Newest Board Member Brings a Fresh Perspective to the LRG
Dr. Joseph Germino, retired medical oncologist who most recently served as the VP of Medical Affairs at Bayer, joins the LRG Board of Directors.
Did You Know? Tissue Testing FREE for GIST Patients!
The Life Raft Group is currently conducting a tissue testing initiative for GIST patients to receive FREE Next-Generation Sequencing (NGS) Testing!
Tissue Testing Project
The Life Raft Group (LRG) is providing you with this information to let you know that comprehensive genomic profiling, also known as biomarker testing or molecular testing, is a crucial step in understanding the genomic factors that play a role in a GIST diagnosis. Bayer Pharmaceuticals, in partnership with The Life Raft Group (LRG), has extended a research collaboration to broaden access to comprehensive genomic testing (CGT) for Gastrointestinal Stromal Tumor (GIST) patients.
La Jolla Provided a Beautiful Backdrop for Our Three-Day July Event
The Life Raft Group and UCSD hosted a three-day event at University of California, San Diego UCSD-Moores Cancer Center from July 13th through July 15th. A GIST Awareness Day (GAD) event took place on July [...]
Stivarga Approved for GIST in EU
The European Commission recently announced that Stivarga (regorafenib) from Bayer has been approved in the European Union (EU) as a third line treatment for GIST.
GIST Awareness Day Highlighted in New Press Release
Coverage of GIST Awareness Day continues with this press release that calls attention to our awareness campaign and our support for the global GIST community.
Stivarga Approved to Treat GIST Patients in Japan
Stivarga has just been approved in Japan for the treatment of GIST. Keep reading for more information.Official Stivarga Press Release:Bayer HealthCare has received approval from the Japanese authorities (MHLW) for the marketing of Regorafenib (Stivarga) [...]
Stivarga becomes first FDA-approved third-line drug treatment for GIST
The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, approved Bayer Pharmaceutical’s drug, Stivarga, for use as a third-line treatment for advanced GIST in February.
FDA approves Stivarga for advanced GIST
The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, has approved Bayer Pharmaceutical's drug, Stivarga, for use as a third-line treatment for advanced GIST.
Patients Face Numerous Obstacles In Quest For Life-Saving Treatment
“It was such a frustrating time. It was awful,” Linda says, recalling how doctors had recommended she give Glaxo-SmithKline’s drug Votrient a shot but was unable to get Jessica’s insurance company to cover it despite appeals documented by GIST specialists.